home.social

#abbvie — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #abbvie, aggregated by home.social.

  1. AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
    #Europe #EU #AbbVie #AllerganAesthetics #Boey #Europeanaesthetics #EuropeanUnion #SimplyWallSt #treatmentduration
    europesays.com/europe/96977/

  2. Allergan Aesthetics receives approval for Boey® , for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

    Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult…
    #Europe #EU #ABBV #AbbVie #nyse-abbv #pharmaceutical-investing
    europesays.com/europe/96688/

  3. Allergan Aesthetics receives approval for Boey® , for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients byteseu.com/2203741/ #abbv #AbbVie #Europe #NyseAbbv #PharmaceuticalInvesting

  4. Why US multinationals keep choosing Ireland. It’s not just the tax or workforce – The Irish Times

    If you ask US multinationals why they choose Ireland as a base for investment, they’ll talk about the…
    #NewsBeep #News #Economy #AbbVie #Alphabet #Apple #Business #feargal-orourke #GileadSciences #ida-ireland #merck #Microsoft #stryker #UK #UnitedKingdom
    newsbeep.com/uk/684198/

  5. EU Approves Expanded Use of ABBV’s Tepkinly in Follicular Lymphoma

    AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or…
    #Europe #EU #ABBV #AbbVie #adultpatients #AmarinCorporation #EuropeanCommission #EuropeanUnion #follicularlymphoma #R/RFL #systemictherapy #ZacksInvestmentResearch
    europesays.com/europe/88824/

  6. AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

    TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for…
    #Europe #EU #EuropeanCommission #ABBV #AbbVie #nyse-abbv #pharmaceutical-investing
    europesays.com/europe/87767/

  7. AbbVie TEPKINLY approved in EU for follicular lymphoma

    TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for…
    #Europe #EU #EuropeanCommission #ABBV #AbbVie #epcoritamab #follicularlymphoma #marketingauthorization #oncology #TEPKINLY
    europesays.com/europe/87729/

  8. 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

    Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…
    #NewsBeep #News #Personalfinance #ABBV #AbbVie #AU #Australia #Business #dividendyields #Finance #freecashflow #ModerateRisk #PersonalFinance #top10AIstocks #traditionalIRA #Verizon
    newsbeep.com/au/758541/

  9. AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection

    MAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV)…
    #Europe #EU #ABBV #AbbVie #European #nyse-abbv #pharmaceutical-investing
    europesays.com/europe/77019/

  10. AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

    Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase…
    #Europe #EU #EuropeanCommission #ABBV #AbbVie #nyse-abbv #pharmaceutical-investing
    europesays.com/europe/55761/

  11. AbbVie: EC expands VENCLYXTO label in first-line CLL

    Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase…
    #Europe #EU #ABBV #AbbVie #chroniclymphocyticleukemia #CLLtreatment #European #EuropeanCommission #labelexpansion #VENCLYXTO #venetoclax
    europesays.com/europe/55608/

  12. Analysis: Market Outlook for AbbVie Following Recent Earnings Performance

    📰 Original title: Watch: Why Investors Are Still Worried About AbbVie

    🤖 IA: It's clickbait ⚠️
    👥 Usuarios: It's clickbait ⚠️

    View full AI summary: killbait.com/en/analysis-marke

    #business #abbvie #inves...

  13. Analysis: Market Outlook for AbbVie Following Recent Earnings Performance

    📰 Original title: Watch: Why Investors Are Still Worried About AbbVie

    🤖 IA: It's clickbait ⚠️
    👥 Usuarios: It's clickbait ⚠️

    View full AI summary: killbait.com/en/analysis-marke

    #business #abbvie #inve...

  14. Best Healthcare Stocks to Buy After the Market Pullback

    Equity markets have moved in the wrong direction over the past three weeks. They may not rebound and…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #AbbVie #CVSHealth #geopoliticalissues #Health
    newsbeep.com/us/535135/

  15. ¿Por qué AbbVie prevé ganancias récord en 2026 gracias a la inmunología? La farmacéutica supera las expectativas y anticipa un crecimiento sostenido impulsado por nuevos medicamentos sagaroja.com/es/blog/empresas/ #Abbvie #Farmacuticas #Inmunologa

  16. ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

    AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #ZacksInvestmentResearch
    newsbeep.com/us/115696/

  17. ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

    AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #ZacksInvestmentResearch
    newsbeep.com/us/115696/

  18. ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

    AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
    #NewsBeep #News #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #UK #UnitedKingdom #ZacksInvestmentResearch
    newsbeep.com/uk/96577/

  19. AbbVie (ABBV)

    #Tradingan - #Grafik #harga #saham #AbbVie (ABBV) hari ini untuk membantu #analisa #pasar sebelum memulai #investasi dan #trading saham AbbVie #ABBV. AbbVie Inc. (NYSE: ABBV) adalah #perusahaan #biofarmasi global yang berfokus pada #pengembangan dan #komersialisasi obat-obatan #inovatif, terutama di bidang #imunologi, onkologi, neurosains, dan virologi. Perusahaan ini terkenal berkat obat Humira, salah satu obat terlaris di dunia untuk penyakit autoimun…

    tradingan.com/abbvie

  20. Bloomberg: #Alphabet #shares rally 6% in early trading as the company's strength in #search #advertising helped profit beat estimates. #AbbVie, #Colgate-Palmolive and #Schlumberger are slated to report later. #Stocks and the dollar edge higher. #markets

  21. 5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  22. AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma